View by Specialty

Headline News

View more

FDA approves Lutathera for children with gastroenteropancreatic neuroendocrine tumors

April 25, 2024
2 min read
Save

FDA approves Lutathera for children with gastroenteropancreatic neuroendocrine tumors

FDA approves Lutathera for children with gastroenteropancreatic neuroendocrine tumors

The FDA approved lutetium Lu 177 dotatate for the treatment of pediatric patients aged 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut and hindgut tumors.

View more Headline News
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails

Resources

View more

Healio Special Report: Health Care and Politics

This collection of articles includes the latest news on health care laws and policies in the United States and their impact on patient care.

View resource

Race and Medicine

Racially diverse paper dolls with stethoscope

This collection seeks to bring together research on racial disparities across our specialties along with perspectives from physicians from various racial backgrounds.

View resource
View more Resources
View more Meeting News
View meeting calendar

Podcasts

View more
Hematology/Oncology Oncology Overdrive
April 18, 2024
48 min listen

Learning Leadership with Jonathan D. Licht, MD

Hematology/Oncology Oncology Overdrive
April 04, 2024
32 min listen

Global GI Oncology with Aparna Parikh, MD

View more Podcasts

Blogs & Columns

View more
ASTCT Update is sponsored by American Society for Transplantation and Cellular Therapy, which is dedicated to the application and success of blood and marrow transplantation and related cellular therapies. The blog provides essential updates about research advances, health policy and clinical best practices to ensure optimal patient care. ASTCT provides additional practice resources on its website.



A column for advanced practice providers to share research advances, and discuss day-to-day practice and regulatory concerns.

View more Blogs & Columns